N-[5-(二氨基亚甲基氨基)-1-(萘-2-基氨基)-1-氧代戊烷-2-基]苯甲酰胺 | 305-09-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[5-(二氨基亚甲基氨基)-1-(萘-2-基氨基)-1-氧代戊烷-2-基]苯甲酰胺
• 中文别名: 二环[3.1.0]己烷-2,6-二羧酸,2-氨基-6-氟-,(1R,2S,5R,6S)-rel-
• 英文名称: Nα-benzoyl-DL-arginine β-naphthylamide
• 英文别名: α-N-benzoyl-D,L-arginine-2-naphthylamide；α-N-benzoyl-DL-arginine-2-naphthylamide；α-benzoyl-DL-arg-β-naphthylamide；α-N-benzoylarginine-2-naphthylamide；Bz-DL-Arg-β-naphthylamide；BANA；N-{5-carbamimidamido-1-[(naphthalen-2-yl)amino]-1-oxopentan-2-yl}benzamide；N-[5-(diaminomethylideneamino)-1-(naphthalen-2-ylamino)-1-oxopentan-2-yl]benzamide
• CAS: 305-09-9
• 化学式: C₂₃H₂₅N₅O₂
• 分子量: 403.484
• InChiKey: DEFAKPKFXYITPZ-UHFFFAOYSA-N

物化性质

• 溶解度：
  52.2 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  123
• 氢给体数：
  4
• 氢受体数：
  3

安全信息

• 海关编码：
  2925290090

反应信息

• 作为反应物：
  描述：

  N-[5-(二氨基亚甲基氨基)-1-(萘-2-基氨基)-1-氧代戊烷-2-基]苯甲酰胺 在 (8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate,bromide 、 cathepsin B 作用下， 生成 2-萘胺
  参考文献：
  名称：

  Inhibitory effects of quaternary ammonium compounds on lysosomal degradation of endogenous proteins.

  摘要：

  研究了定量铵化合物对离体溶酶体中内源性蛋白质降解的影响。研究发现，浓度高于 0.85 mM 的对联苯甲基-(dl-丙基-α-托品铵)溴化物（BTTB）可按比例抑制溶酶体蛋白水解。此外，还研究了其他三价铵化合物，如 N-甲基溴化铵（NMA）、十六烷基三甲基溴化铵（CTAB）、土茯苓碱和加拉敏，它们在是否存在能破坏溶酶体膜的 Triton X-100 的情况下也能起作用。在这四种化合物中，NMA 是最有效的蛋白水解抑制剂，浓度为 1 mM 时对完整溶酶体的抑制率为 25%。当溶酶体经过 Triton X-100 处理后再对这些化合物进行检测时，所有药物的效果都会增强，这表明这些药物在溶酶体中积累后，会通过与溶酶体蛋白酶的直接相互作用发挥作用。对 NMA 对溶酶体蛋白酶 B（一种典型的溶酶体蛋白酶）的影响进行的动力学分析证实了这一点。

  DOI：

  10.1248/cpb.37.516
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 钯 、 溶剂黄146 作用下， 生成 N-[5-(二氨基亚甲基氨基)-1-(萘-2-基氨基)-1-氧代戊烷-2-基]苯甲酰胺
  参考文献：
  名称：

  Riedel et al., Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1959, vol. 316, p. 61,65

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF ARGININE GINGIPAIN<br/>[FR] INHIBITEURS D'ARGININE GINGIPAÏNE
  申请人：CORTEXYME INC

  公开号：WO2017083433A1

  公开（公告）日：2017-05-18

  The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.

  本发明通常涉及治疗靶向细菌 Porphyromonas gingivalis 的治疗药物，包括其蛋白酶精氨酸龈蛋白酶 A/B（Rgp），以及它们用于治疗与 P. gingivalis 感染相关的疾病，包括脑部疾病如阿尔茨海默病。在某些实施例中，本发明提供根据本文所述的 Formula I 的化合物及其药用盐。
• INHIBITORS OF LYSINE GINGIPAIN
  申请人：Cortexyme, Inc.

  公开号：US20160096830A1

  公开（公告）日：2016-04-07

  The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis , including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.

  本发明通常涉及针对细菌牙龈脓红素Porphyromonas gingivalis及其蛋白酶赖氨酸龈蛋白酶（Kgp）的治疗方法，以及它们用于治疗与P. gingivalis感染相关的疾病，包括脑部疾病如阿尔茨海默病。在某些实施例中，本发明提供根据本文所述的I式化合物及其药用可接受的盐。
• Amide-based compounds, production, recovery, purification and uses thereof
  申请人：——

  公开号：US20040059108A1

  公开（公告）日：2004-03-25

  Methods are disclosed of producing and purifying at least one amide. In accordance with one of the methods disclosed herein, the at least one amide is produced by providing an organic liquid comprising at least one oxime, providing at least one catalyst, adding the at least one catalyst to the organic liquid to form a rearrangement mass, wherein the rearrangement mass comprises at least one amide, at least one impurity, and the at least one catalyst, and heating the rearrangement mass to a temperature of at least about 115° C. for a period of time in order to sulfonate, break down and/or reduce the concentration of some of the at least one impurity in the rearrangement mass.

  本公开了生产和纯化至少一种酰胺的方法。根据本文披露的方法之一，至少一种酰胺通过提供含有至少一种肟的有机液体，提供至少一种催化剂，将至少一种催化剂加入有机液体中形成重排物质，其中重排物质包括至少一种酰胺、至少一种杂质和至少一种催化剂，并将重排物质加热至至少约115°C的温度一段时间，以磺化、分解和/或减少重排物质中至少一种杂质的浓度。
• Cyclin Based Inhibitors of CDK2 and CDK4
  申请人：University of South Carolina

  公开号：US20150011730A1

  公开（公告）日：2015-01-08

  Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation.

  对肽抑制剂与细胞周期素D和细胞周期素A凹槽的结构和功能分析已经进行了研究，并用于设计肽，为结构活性关系提供基础，具有改善结合能力并具有潜力作为化学生物学探针，潜在诊断工具和治疗增生性疾病，包括癌症和炎症。
• Detection of Bacteroides gingivalis
  申请人：THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK

  公开号：EP0292708A2

  公开（公告）日：1988-11-30

  The present invention relates to the detection of B. gingivalis by the specific ability of B. gingivalis to hydrolyze N-carbobenzoxy-glycyl-glycyl-L-arginine-B-napthylamide deriva­tives. The present invention also relates to the use of assay systems which inhibit serum amino peptidase and enhance the detection of the B. gingivalis N-CBz-Gly-Gly-Arg peptidase. The assay system inhibits the serum enzyme by the use of a serum aminopeptidase inhibitor which inhibits the activity of serum aminopeptidase to a greater extent than it inhibits the activity of B. gingivalis N-CBz-Gly-Gly-Arg peptidase. The assay system also increases the reliability of detection of the B. gingivalis enzyme by the use of enhancing materials which enhance the enzyme activity of B. gingivalis N-CBz-Gly-Gly-Arg peptidase to a greater extent than such materials enhance the enzyme activity of serum aminopeptidase.

  本发明涉及通过牙龈杆菌水解 N-羧基苯氧基-甘氨酰-甘氨酰-L-精氨酰-B-萘酰胺衍生物的特异性能力来检测牙龈杆菌。本发明还涉及抑制血清氨基肽酶并提高牙龈杆菌 N-CBz-Gly-Gly-Arg 肽酶检测能力的检测系统的使用。该检测系统通过使用血清氨基肽酶抑制剂来抑制血清酶，该抑制剂对血清氨基肽酶活性的抑制程度大于对牙龈杆菌 N-CBz-Gly-Gly-Arg 肽酶活性的抑制程度。该检测系统还通过使用增强材料提高牙龈杆菌 N-CBz-Gly-Gly-Arg 肽酶的酶活性，其增强程度大于此类材料对血清氨肽酶酶活性的增强程度，从而提高检测牙龈杆菌酶的可靠性。